EU-Japan extend mutual recognition to biologics and APIs

By Ben Hargreaves

- Last updated on GMT

(Image: Pixabay/Rawpixel)
(Image: Pixabay/Rawpixel)

Related tags Ema Japan Mutual recognition

The EU and Japan have extended their current mutual recognition agreement to include certain biologic medicines, sterile medicines and APIs.

The announcement builds on a previous agreement, signed in May 2004, which saw both the European Union (EU) and Japan mutually recognise good manufacturing practice (GMP) inspections in each other’s territory.

The new agreement broadens this to contain certain biological medicines, including immunologicals and vaccines, which will no longer need to be inspected once they have been delivered to the other’s territory.

Beyond this, it also includes chemical pharmaceuticals, homeopathic medicinal products, vitamins, minerals and herbal medicines. Any active pharmaceutical ingredients and sterile products that are included in any of these treatments will also not need to be inspected.

The European Medicines Agency (EMA) explained the advantages of the deal in a statement​: “Thanks to this agreement, regulatory authorities in the EU and Japan can make better use of their inspections resources by reducing duplication of inspections in each other’s territory.”

Mutual recognition is a growing trend across different nations, as the benefits of not having to replicate inspection reports ease the burden both for regulators, as referenced by the EMA statement, but also for the industry​.

The US, for example, has been particularly keen to extend its mutual agreements​ with the EU.

The announcement by the EMA comes only a day after the EU and Japan concluded its 25th​ summit. The meeting saw the two countries enter a significant free trade deal​ between two of the largest economic regions in the world.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Webinars